Organovo Holdings Inc
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with … Read more
Organovo Holdings Inc (ONVO) - Total Assets
Latest total assets as of December 2024: $3.84 Million USD
Based on the latest financial reports, Organovo Holdings Inc (ONVO) holds total assets worth $3.84 Million USD as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Organovo Holdings Inc - Total Assets Trend (2011–2024)
This chart illustrates how Organovo Holdings Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Organovo Holdings Inc - Asset Composition Analysis
Current Asset Composition (March 2024)
Organovo Holdings Inc's total assets of $3.84 Million consist of 62.0% current assets and 38.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.7% |
| Accounts Receivable | $33.00K | 0.5% |
| Inventory | $297.00K | 4.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $8.00K | 0.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Organovo Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Organovo Holdings Inc's current assets represent 62.0% of total assets in 2024, a decrease from 100.0% in 2011.
- Cash Position: Cash and equivalents constituted 45.7% of total assets in 2024, up from 41.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 4.7% of total assets.
Organovo Holdings Inc Competitors by Total Assets
Key competitors of Organovo Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Organovo Holdings Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Organovo Holdings Inc generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Organovo Holdings Inc is currently not profitable relative to its asset base.
Organovo Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.72 | 3.67 | 15.65 |
| Quick Ratio | 0.72 | 3.67 | 15.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-837.00K | $ 4.54 Million | $ 26.51 Million |
Organovo Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Organovo Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.89 |
| Latest Market Cap to Assets Ratio | 0.38 |
| Asset Growth Rate (YoY) | -68.7% |
| Total Assets | $6.35 Million |
| Market Capitalization | $2.41 Million USD |
Valuation Analysis
Below Book Valuation: The market values Organovo Holdings Inc's assets below their book value (0.38 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Organovo Holdings Inc's assets decreased by 68.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Organovo Holdings Inc (2011–2024)
The table below shows the annual total assets of Organovo Holdings Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-03-31 | $6.35 Million | -68.74% |
| 2023-03-31 | $20.31 Million | -38.99% |
| 2022-03-31 | $33.30 Million | -16.59% |
| 2021-03-31 | $39.92 Million | +40.35% |
| 2020-03-31 | $28.44 Million | -29.99% |
| 2019-03-31 | $40.62 Million | -18.47% |
| 2018-03-31 | $49.83 Million | -27.97% |
| 2017-03-31 | $69.18 Million | +2.37% |
| 2016-03-31 | $67.58 Million | +26.34% |
| 2015-03-31 | $53.49 Million | +6.58% |
| 2014-03-31 | $50.19 Million | +199.64% |
| 2013-03-31 | $16.75 Million | +391689.47% |
| 2012-03-31 | $4.28K | 0.00% |
| 2011-03-31 | $4.28K | -- |